SMARCA4 and sarcoma: Partial responses to PD1/PDL1 blockade have been reported in PDL1-positive SMARCA4-deficient thoracic sarcomas with pembrolizumab [130,131,132], nivolumab [133] and atezolizumab plus bevacizumab combined with CT [134,135].